Upstate Active Clinical Trials

Study Title:

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON AS ADJUNCTIVE THERAPY FOR PARKINSON'S DISEASE IN LEVODOPA-TREATED ADULTS WITH MOTOR FLUCTUATIONS

What is the purpose of the study? (in Layman's terms, please describe the study)

To assess the effect of tavapadon on the change from baseline in total daily hours of “on” time without troublesome
dyskinesia in L-Dopa-treated subjects with PD who are experiencing motor fluctuations.

Upstate Institutional Review Board (IRB) Number:

1569679

Patient Age Group:

Adults

Principal Investigator:

Dragos L Mihaila

What is involved if I participate?

• How long is the study?
  Approximately 7 months.

ClinicalTrials.Gov ID:

NCT04542499

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Marielle N Posmik
Phone: 315-464-1670
Email: Posmikm@upstate.edu

Return to Previous Page || Search Again